Want to see BEAM full AI Analyst Report?
BEAM Stock Chart & Stats
$31.03
-$0.81(-3.13%)
At close: 4:00 PM EDT
$31.03
-$0.81(-3.13%)
Day’s Range― - ―
52-Week Range$20.23 - $38.26
Previous CloseN/A
Volume1.81M
Average Volume (3M)1.70M
Market Cap
$2.52B
Enterprise Value$2.67K
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$247.36M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Nov 09, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend Yield4.8%
Share Statistics
EPS (TTM)-0.82
Shares Outstanding103,287,670
10 Day Avg. Volume1,756,340
30 Day Avg. Volume1,697,478
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.30Price Target Upside68.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.43
Revenue Forecast (FY)$51.26M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow-to-moderate debt relative to equity, alongside sizable equity, gives Beam more financial flexibility than a highly levered biotech. That cushion can support continued clinical and platform investment while reducing near-term balance-sheet pressure, provided losses do not erode it.
Precision Editing PlatformBeam’s base-editing platform targets precise single-letter DNA changes, while its pipeline spans genetic diseases and oncology. This technology focus and breadth create multiple avenues for clinical value creation and partnering, reducing reliance on any single candidate.
Improved Gross ProfitMaterial margin improvement and a return to positive gross profit in 2025 indicate some operating progress despite ongoing losses. If sustained, better economics could improve the path toward scale as candidates advance, although TTM profitability remains pressured.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow means Beam must continue funding research and development without internally generated cash. Ongoing reliance on external funding can constrain strategic flexibility and may pressure the company to narrow programs or raise capital.
Sustained UnprofitabilityPersistent operating and net losses show that Beam has not yet converted its research platform and clinical pipeline into a profitable business. Until commercialization or collaboration economics improve, losses can continue consuming equity and delaying durable earnings generation.
Revenue VolatilityVolatile revenue, including a sharp TTM contraction, makes Beam’s current funding profile less predictable than that of a commercial-stage biotech. Uneven collaboration or licensing income can complicate planning and leave cash needs highly dependent on deal timing and development milestones.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $20.23 and its highest was $38.26 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.52B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 58 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Aug 04, 2026. The company reported -$1.18 earnings per share for the quarter, missing the consensus estimate of -$1.106 by -$0.074.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of 4.8%. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.15.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 103,287,670 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.18 in its last earnings report, missing expectations of -$1.106. Following the earnings report the stock price went up 9.417%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.30 (68.55% Upside)
$52.30 (68.55% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 67%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 12%
Bearish news 12%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Beam Therapeutics
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Stock 12 Month Forecast
Average Price Target
$52.30
▲(68.55% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
3.36% Insiders
21.76% Mutual Funds
43.63% Other Institutional Investors
1.47% Public Companies and Individual Investors